Ainos, Inc.
AIMDHealthcare|Biotechnology|US
$0.70
+0.07 (+11.13%)
Cash / Share
$0.19
Financials
Financial Snapshot
Market Cap
$5.2M
Enterprise Value
$17.5M
Revenue (TTM)
$13.6K
Net Income (TTM)
-$14.5M
Cash & Investments
$1.4M
Net Cash
-$12.4M
Free Cash Flow (TTM)
-$4.5M
Operating CF (TTM)
-$4.5M
Debt/Equity
4.21
Cash Runway & Burn Rate
Cash on Hand
$1.4M
Quarterly Burn
$1.1M
Monthly Burn
$372.6K
Est. Runway
~1.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $134.1K | $2.0M | $1.3M | $409.0K | $22.2K | $1.8M | $1.9M | $1.9M | $3.9M | $417.4K | $1.4M | |
| Operating Cash Flow | -$520.8K | -$542.7K | -$1.0M | -$909.5K | -$499.6K | -$1.2M | -$3.0M | -$4.7M | -$5.8M | -$4.6M | -$4.5M | |
| Free Cash Flow | -$669.1K | -$591.8K | -$1.0M | -$922.6K | -$506.8K | -$1.4M | -$3.7M | -$4.8M | -$5.8M | -$4.6M | -$4.5M | |
| Capital Expenditure | -$148.3K | -$49.1K | -$7.3K | -$13.1K | -$7.2K | -$143.8K | -$633.8K | -$93.0K | -$21.3K | -$34.6K | -$22.9K | |
| Financing Cash Flow | $782.1K | $2.4M | $255.0K | $55.0K | $120.0K | $3.2M | $3.9M | $4.9M | $8.0M | $1.0M | $4.7M |
R&D Spending
R&D (TTM)
$6.5M
R&D Intensity
47527.9%
R&D Growth vs Prior
-16.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $250.9K | $77.7K | $11.7K | $16.6K | $594.6K | $3.5M | $122.1K | $20.7K | $124.2K | $13.6K | |
| R&D Expense | $0.00 | $0.00 | $32.6K | $52.5K | $389.00 | $1.9M | $6.8M | $7.3M | $8.4M | $7.7M | $6.5M | |
| R&D % of Revenue | — | 0.0% | 41.9% | 447.6% | 2.3% | 323.0% | 194.5% | 5992.4% | 40590.1% | 6241.9% | 47527.9% | |
| SG&A | $667.1K | $770.4K | $1.3M | $1.5M | $1.4M | $2.4M | $8.5M | $5.6M | $5.4M | $1.6M | $2.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $250.9K | $77.7K | $11.7K | $16.6K | $594.6K | $3.5M | $122.1K | $20.7K | $124.2K | $13.6K | |
| Cost of Revenue | $26.0K | $60.3K | $64.9K | $8.8K | $11.3K | $184.2K | $2.1M | $375.8K | $52.6K | $4.8M | $4.8M | |
| Gross Profit | -$26.0K | $190.6K | $12.8K | $3.0K | $5.3K | $410.4K | $1.4M | -$253.7K | -$31.9K | -$4.7M | -$4.8M | |
| R&D | $0.00 | $0.00 | $32.6K | $52.5K | $389.00 | $1.9M | $6.8M | $7.3M | $8.4M | $7.7M | $6.5M | |
| SG&A | $667.1K | $770.4K | $1.3M | $1.5M | $1.4M | $2.4M | $8.5M | $5.6M | $5.4M | $1.6M | $2.5M | |
| Operating Income | -$667.1K | -$579.8K | -$1.3M | -$1.6M | -$1.4M | -$3.9M | -$14.0M | -$13.2M | -$13.8M | -$14.0M | -$13.8M | |
| Interest Expense | $2.9K | $37.6K | $4.0K | $885.00 | $10.2K | $18.7K | $53.5K | $144.2K | $616.5K | $711.9K | $730.5K | |
| Pretax Income | -$670.0K | -$617.4K | -$1.3M | -$1.6M | -$1.5M | -$3.9M | -$14.0M | -$13.8M | -$14.9M | -$14.8M | -$14.5M | |
| Net Income | -$670.0K | -$617.4K | -$1.3M | -$1.6M | -$1.5M | -$3.9M | -$14.0M | -$13.8M | -$14.9M | -$14.8M | -$14.5M | |
| EPS (Diluted) | -0.50 | -0.41 | -0.56 | -0.74 | -2.69 | -2.59 | -5.14 | -3.36 | -1.56 | -3.46 | -2.52 | |
| EBITDA | -$641.2K | -$539.8K | -$1.3M | -$1.6M | -$1.4M | -$1.8M | -$9.1M | -$8.8M | -$9.4M | -$9.3M | -$9.0M | |
| Shares Out. (M) | 1.34 | 1.51 | 2.38 | 2.15 | 0.54 | 1.51 | 2.73 | 4.10 | 9.50 | 4.27 | 7.36 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $134.1K | $2.0M | $1.3M | $409.0K | $22.2K | $1.8M | $1.9M | $1.9M | $3.9M | $417.4K | $1.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $262.4K | $2.1M | $1.3M | $445.3K | $76.4K | $2.2M | $2.8M | $2.5M | $4.3M | $1.1M | $2.2M | |
| Total Assets | $462.7K | $2.3M | $1.5M | $596.6K | $260.3K | $40.8M | $37.1M | $31.8M | $28.8M | $20.9M | $19.6M | |
| Total Current Liabilities | $1.3M | $1.8M | $733.6K | $753.3K | $1.1M | $30.6M | $2.5M | $1.3M | $4.0M | $1.1M | $16.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $5.9M | $9.0M | $11.0M | $0.00 | |
| Total Liabilities | $1.3M | $1.8M | $733.6K | $753.3K | $1.1M | $30.6M | $2.5M | $7.4M | $13.3M | $13.3M | $16.3M | |
| Stockholders' Equity | -$809.9K | $470.8K | $730.1K | -$156.7K | -$838.3K | $10.2M | $34.6M | $24.4M | $15.5M | $7.6M | $3.3M | |
| Retained Earnings | -$1.3M | -$1.9M | -$3.2M | -$4.8M | -$6.2M | -$10.1M | -$24.1M | -$37.9M | -$52.7M | -$67.5M | -$74.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$520.8K | -$542.7K | -$1.0M | -$909.5K | -$499.6K | -$1.2M | -$3.0M | -$4.7M | -$5.8M | -$4.6M | -$4.5M | |
| Capital Expenditure | -$148.3K | -$49.1K | -$7.3K | -$13.1K | -$7.2K | -$143.8K | -$633.8K | -$93.0K | -$21.3K | -$34.6K | -$22.9K | |
| Free Cash Flow | -$669.1K | -$591.8K | -$1.0M | -$922.6K | -$506.8K | -$1.4M | -$3.7M | -$4.8M | -$5.8M | -$4.6M | -$4.5M | |
| Investing Cash Flow | -$148.3K | -$49.1K | -$7.3K | -$13.1K | -$7.2K | -$180.5K | -$630.2K | -$101.5K | -$125.3K | -$2.2K | $23.1K | |
| Financing Cash Flow | $782.1K | $2.4M | $255.0K | $55.0K | $120.0K | $3.2M | $3.9M | $4.9M | $8.0M | $1.0M | $4.7M | |
| Issuance of Stock | $332.1K | $144.4K | $401.3K | $125.0K | $0.00 | $0.00 | $1.8M | $0.00 | $0.00 | $2.0M | $1.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$301.00 | $0.00 | -$260.00 | $0.00 | |
| Net Debt Issuance | $262.5K | $95.0K | $0.00 | -$70.1K | $120.0K | $3.1M | $2.1M | $5.3M | $8.1M | -$1.0M | $2.8M | |
| Stock Based Comp. | $0.00 | $106.3K | $100.4K | $0.00 | $524.8K | $150.3K | $6.4M | $1.1M | $3.5M | $1.7M | $4.3M | |
| Net Change in Cash | $113.0K | $1.8M | -$761.5K | -$867.6K | -$386.8K | $1.7M | $101.9K | $32.3K | $2.0M | -$3.5M | $199.7K |
Dilution Tracker
Shares outstanding grew 686.4% over 5 years — significant dilution
Shares Outstanding
7M
5-Year Share Growth
+686.4%
Stock Issuance (TTM)
$1.9M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.34 | 1.51 | 2.38 | 2.15 | 0.54 | 1.51 | 2.73 | 4.10 | 9.50 | 4.27 | 7.36 | |
| Change vs Prior % | — | 12.5% | 57.3% | -9.7% | -74.7% | 178.1% | 80.6% | 50.3% | 131.9% | -55.1% | 72.3% | |
| Stock Issuance | $332.1K | $144.4K | $401.3K | $125.0K | $0.00 | $0.00 | $1.8M | $0.00 | $0.00 | $2.0M | $1.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$301.00 | $0.00 | -$260.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $106.3K | $100.4K | $0.00 | $524.8K | $150.3K | $6.4M | $1.1M | $3.5M | $1.7M | $4.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 76.0% | 16.5% | 25.2% | 31.9% | 69.0% | 39.9% | -207.8% | -153.7% | -3767.2% | -34987.5% | |
| Operating Margin % | — | -231.0% | -1717.2% | -13472.1% | -8696.7% | -650.5% | -397.1% | -10815.0% | -66772.2% | -11268.3% | -101210.2% | |
| Net Margin % | — | -246.0% | -1722.3% | -13487.2% | -8758.2% | -654.0% | -398.0% | -11277.0% | -71702.3% | -11897.0% | -106283.3% | |
| EBITDA Margin % | — | -215.1% | -1644.9% | -13282.5% | -8608.0% | -307.0% | -259.1% | -7169.2% | -45560.2% | -7472.9% | -65872.8% | |
| FCF Margin % | — | -235.8% | -1307.8% | -7864.5% | -3059.8% | -234.4% | -104.4% | -3920.7% | -28122.9% | -3744.7% | -33046.9% | |
| ROE % | 82.7% | -131.1% | -183.4% | 1009.8% | 173.0% | -38.1% | -40.4% | -56.3% | -95.8% | -195.3% | -217.5% | |
| ROA % | -144.8% | -26.9% | -91.5% | -265.2% | -557.3% | -9.5% | -37.7% | -43.2% | -51.6% | -70.8% | -73.9% | |
| ROIC % | 3622.1% | -42.7% | -107.3% | -548.9% | -1255.6% | -28.0% | -38.9% | -43.2% | -49.7% | -70.7% | -80.5% | |
| R&D / Revenue % | — | 0.0% | 41.9% | 447.6% | 2.3% | 323.0% | 194.5% | 5992.4% | 40590.1% | 6241.9% | 47527.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -100.0% | 0.0% | -69.0% | -84.9% | 41.2% | 3489.7% | 492.0% | -96.5% | -83.0% | 499.0% | |
| Gross Profit | -45.8% | 834.4% | -93.3% | -77.0% | 78.6% | 7663.6% | 242.4% | -118.1% | 87.4% | -14577.8% | |
| Operating Income | -28.3% | 13.1% | -130.2% | -18.4% | 8.9% | -168.5% | -261.4% | 5.5% | -4.8% | -1.1% | |
| Net Income | -28.4% | 7.9% | -116.8% | -18.2% | 8.3% | -168.1% | -260.2% | 1.7% | -7.9% | 0.6% | |
| EPS (Diluted) | -28.2% | 18.0% | -36.6% | -32.1% | -263.5% | 3.7% | -98.5% | 34.6% | 53.6% | -121.8% | |
| Operating Cash Flow | -42.1% | -4.2% | -86.0% | 9.9% | 45.1% | -150.2% | -143.3% | -54.4% | -23.7% | 20.5% | |
| Free Cash Flow | -77.0% | 11.6% | -71.8% | 9.2% | 45.1% | -175.0% | -163.6% | -30.3% | -21.8% | 20.2% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 61.1% | -99.3% | 493639.1% | 256.4% | 6.9% | 15.0% | -7.9% | |
| SG&A Expense | 27.8% | 15.5% | 70.7% | 16.4% | -5.6% | 63.1% | 262.1% | -34.0% | -4.3% | -71.0% | |
| Total Assets | 294.8% | 395.8% | -36.2% | -59.2% | -56.4% | 15583.3% | -9.1% | -14.2% | -9.5% | -27.6% | |
| Book Value / Share | -71.6% | 151.7% | -1.4% | -123.8% | -2014.9% | 537.4% | 88.0% | -53.0% | -72.6% | 8.5% | |
| Debt | 105.8% | 12.0% | -42.1% | -13.4% | 114.4% | 279.9% | -65.0% | 370.1% | 101.2% | -8.3% | |
| Diluted Shares | 0.0% | 12.5% | 57.3% | -9.7% | -74.7% | 178.1% | 80.6% | 50.3% | 131.9% | -55.1% |
Valuation
P/E (TTM)At Loss
P/S378.98
10Y Low / Med / High12.01 / 800.19 / 10504.36
P/B1.56
10Y Low / Med / High0.93 / 1.72 / 186.82
EV/EBITDAAt Loss
EV/Revenue1290.01
10Y Low / Med / High11.85 / 803.34 / 10507.39
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.19
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -114.80 | -140.00 | -102.50 | -77.57 | -21.34 | -121.63 | -3.02 | -3.05 | -1.46 | -0.47 | -0.28 | |
| P/S Ratio | 0.00 | 345.62 | 1754.89 | 10504.36 | 1882.07 | 800.19 | 12.01 | 343.99 | 1045.31 | 56.41 | 378.98 | |
| P/B Ratio | -95.18 | 184.21 | 186.82 | -786.48 | -37.19 | 46.66 | 1.22 | 1.72 | 1.40 | 0.93 | 1.56 | |
| EV/EBITDA | -121.26 | -158.64 | -106.09 | -79.11 | -22.52 | -261.64 | -4.57 | -5.26 | -3.15 | -1.90 | -1.96 | |
| EV/Revenue | 0.00 | 341.26 | 1745.07 | 10507.39 | 1938.27 | 803.34 | 11.85 | 377.39 | 1436.41 | 141.65 | 1290.01 |
Analyst Estimates & Quality
Altman Z-Score
-8.33
Distress
Piotroski F-Score
2
Weak